Relmada Therapeutics: Funding, Investors & Team (Sep 2026)
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
Relmada Therapeutics has raised $310M across 2 funding rounds on record, the most recent an undisclosed round of $160M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Relmada Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Relmada Therapeutics Funding Rounds
Relmada Therapeutics raised $150M in a Post-IPO Equity announced in Dec 2021.
4.3 years later, an undisclosed round of $160M was announced in Mar 2026.
Relmada Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Relmada Therapeutics Funding Compared to Other Biotechnology Startups
Relmada Therapeutics' latest round of $160M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Relmada Therapeutics in Biotechnology and New York
Companies Similar to Relmada Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Relmada Therapeutics Funding FAQs
What does Relmada Therapeutics do?
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
How much funding has Relmada Therapeutics raised?
Relmada Therapeutics has raised $310M across 2 rounds on record. The most recent is an undisclosed round of $160M announced in Mar 2026.
When did Relmada Therapeutics last raise funding?
Relmada Therapeutics' most recent funding round on record is an undisclosed round of $160M, announced in Mar 2026.
Who is the CEO of Relmada Therapeutics?
Sergio Traversa is listed as CEO at Relmada Therapeutics.
Where is Relmada Therapeutics headquartered?
Relmada Therapeutics is based in New York, United States.
How many employees does Relmada Therapeutics have?
Relmada Therapeutics is in the 11-50 employee band.
How does Relmada Therapeutics' funding compare to other Biotechnology startups?
Relmada Therapeutics' latest round of $160M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Relmada Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Relmada Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.